Help Privacy Policy Disclaimer
  Advanced SearchBrowse




Journal Article

Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations


Parida,  Shreemanta K.
Department of Immunology, Max Planck Institute for Infection Biology, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)

(Publisher version), 2MB

Supplementary Material (public)
There is no public supplementary material available

Hanekom, W. A., Dockrell, H. M., Ottenhoff, T. H. M., Doherty, T. M., Fletcher, H., McShane, H., et al. (2008). Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations. PLoS Medicine, 5(7): 145, pp. 1033-1036.

Cite as: https://hdl.handle.net/11858/00-001M-0000-000E-C1AE-7
Summary Points * Many new and diverse tuberculosis vaccines are currently under development. * The ability to compare clinical immunogenicity between different candidates would be an important asset. * The World Health Organization (WHO) Initiative for Vaccine Research sponsored three meetings of experts to discuss assay harmonization for new tuberculosis vaccine trials. * We describe advantages and disadvantages of multiple T cell assay approaches and make specific recommendations for phase I/IIa trials. These include introducing a single and simple harmonised assay for all trials.